Menu

The Burning Question About Inflammation: Are Cannabinoids the Cure?

The Scientist is bringing together a panel of experts to discuss their research, and to offer insight into the rewards and challenges of studying a biomedical application for a well-known, but controlled, substance.

Aug 3, 2017
The Scientist Creative Services Team

The Burning Question About Inflammation: Are Cannabinoids the Cure? from thescientistllc on Vimeo.

Simmering, low-level inflammation throughout the body is responsible for many disease processes, ranging from osteoarthritis and cardiovascular disease, to digestive disorders and neurodegeneration. The bioactive molecules, known as cannabinoids, found in plants of the Cannabis species, have been shown to possess powerful anti-inflammatory attributes, and research into their mechanisms of action, efficacy, and tolerability are underway. To explore the potential for cannabinoid-based and/or endocannabinoid-targeted therapeutics in the realm of human disease, and particularly diseases with an inflammatory component, The Scientist is bringing together a panel of experts to discuss their research, and to offer insight into the rewards and challenges of studying a biomedical application for a well-known, but controlled, substance. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • Exogenous and endogenous cannabinoid mechanisms of action in the setting of inflammatory disease
  • Targeting the endocannabinoid system for therapeutic effects

View the Video Now

Meet the Speakers:

Anton Reiner, PhD  
Professor, Department of Anatomy and Neurobiology
University of Tennessee Health Science Center

 

 

Yannick Marchalant, PhD  
Assistant Professor, Departments of Psychology and Neuroscience
Central Michigan University

 

 

Sponsors:

 

 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!